CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA

拓扑替康慢性对流增强递送 (CED) 治疗胶质母细胞瘤

• 批准号: 8495955
• 负责人: JEFFREY N BRUCE
• 金额: $ 8.9万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8495955
• 关键词: Address; Adverse effects; Animal Model; Biopsy; Blood - brain barrier anatomy; Brain; Brain Neoplasms; Catheters; Central Nervous System Diseases; Chronic; Clinical; Clinical Trials; Complex; Convection; Dose; Drug Delivery Systems; Effectiveness; Environment; Excision; Family suidae; Gadolinium; Glioblastoma; Human; Image; Implant; Implantable Pump; Indwelling Catheter; Infusion procedures; Intravenous; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant - descriptor; Malignant Glioma; Measurement; Measures; Methodology; Methods; Microdialysis; Modeling; Monitor; Operative Surgical Procedures; Oral; Outcome; Outcome Measure; Patients; Permeability; Pharmaceutical Preparations; Phase I Clinical Trials; Pump; Radiation; Recurrence; Safety; Sampling; Spectrophotometry; System; Testing; Therapeutic; Time; Tissue Sample; Topoisomerase Inhibitors; Topotecan; Toxic effect; Tracer; Treatment Failure; Validation; brain tissue; chemotherapy; clinical application; conventional therapy; cytotoxic; drug distribution; gadolinium oxide; improved; innovation; neoplastic cell; non-invasive monitor; novel; preclinical study; response; treatment strategy; tumor

DESCRIPTION (provided by applicant): The inability to achieve sufficient intratumoral concentrations of chemotherapeutic drugs in is one of the primary causes of treatment failure in patients with glioblastoma. We have shown in a Phase 1 clinical trial that a topoisomerase inhibitor, topotecan, can be safely and effectively delivered by convection enhanced delivery into patients with recurrent malignant gliomas as a means of overcoming systemic delivery limitations. In this proposal, we will improve this treatment strategy by validating an innovative method for non-invasive monitoring of drug distribution and expanding the duration of infusion by innovating the use of an implantable microinfusion pump. At the conclusion of these studies, the expected outcome will be a novel, measureable strategy to treat patients with recurrent glioblastoma via an implantable pump that can chronically deliver high doses of topotecan into the tumor and surrounding brain to avoid the limitations imposed by conventional systemic delivery. On a broader level, we will have demonstrated, for the first time in humans, the ability to chronically achieve a local-regional distribution of a drug directly into the brain parenchyma.

描述（由申请方提供）：无法达到足够的肿瘤内化疗药物浓度是胶质母细胞瘤患者治疗失败的主要原因之一。我们在1期临床试验中表明，拓扑异构酶抑制剂拓扑替康可以通过对流增强递送安全有效地递送到复发性恶性胶质瘤患者中，作为克服全身递送限制的一种手段。在这项提案中，我们将通过验证一种创新的方法来改善这种治疗策略，该方法用于无创监测药物分布，并通过创新植入式微输注泵的使用来延长输注时间。在这些研究的结论中，预期的结果将是一种新的、可测量的策略，通过植入式泵治疗复发性胶质母细胞瘤患者，该植入式泵可以长期将高剂量的拓扑替康递送到肿瘤和周围大脑中，以避免传统全身递送的限制。在更广泛的层面上，我们将首次在人类身上证明，能够长期实现药物直接进入脑实质的局部区域分布。